Tim Smith

In this interview segment, Chovatiya touched upon the late-breaking data he had presented at RAD 2023 conference on tapinarof cream 1% for younger eczema patients.

In his RAD 2023 conference presentation, Chovatiya discussed data on recent therapies for eczema such as upadacitinib, ruxolitinib, tralokinumab, and dupilumab.

Bunick describes the key safety data from new late-breaking research on upadacitinib for atopic dermatitis that he presented at the Revolutionizing Atopic Dermatitis conference.

This segment of Abuabara’s Q&A interview involved a discussion of some of the other major points covered in her Revolutionizing Atopic Dermatitis presentation on long-term eczema control.

In this interview with Bunick, he describes some of the late-breaking research on upbadacitinib he presented at the the Revolutionizing Atopic Dermatitis conference.

In this Q&A interview with Abuabara, she discusses some of the major takeaways from her Revolutionizing Atopic Dermatitis presentation on long-term control of eczema.

New phase 2 data from the SCRATCH-AD trial found that ruxolitinib 1.5% showed strong results for rapidly reducing itch in eczema patients, an improvement that continued over 28 days.

In this interview segment, Siegfried discussed the major points she hopes clinicians take away from her Revolutionizing Atopic Dermatitis conference talk regarding eczema in infants.

Siegfried spoke on the subjects covered in her presentation at the Revolutionizing Atopic Dermatitis conference, specifically the different conditions that can mirror eczema in infancy.

In her presentation at the Revolutionizing Atopic Dermatitis conference, Melinda Gooderham spoke about 4 specific upcoming therapies set to arrive this year for patients with eczema, including 2 nonsteroidal topicals.

In this interview, King discussed his Revolutionizing Atopic Dermatitis presentation on his views about the safety of JAK inhibitors in otherwise healthy eczema patients.

During another interview segment, Silverberg highlighted some new insights into oral JAK-inhibitors from his presentation at the Revolutionizing Atopic Dermatitis conference.

In this interview segment, Silverberg discussed some of the major takeaways from his Revolutionizing Atopic Dermatitis presentation on eligibility for systemic treatments.

Eichenfield discussed the major takeaways from his Revolutionizing Atopic Dermatology conference presentation regarding recent data on PDE4 and JAK inhibitors for eczema patients.

During this interview segment, Singh spoke on the ways in which dermatologists may help infants manage atopic dermatitis, as well as her outlook on the future of treatment.

In this interview, Singh described the major takeaways from her presentation on allergy testing for infants which she gave at the Revolutionizing Atopic Dermatitis conference.

Eichenfield discussed his first presentation at the Revolutionizing Atopic Dermatitis conference, with his discussion covering systemic atopic dermatitis treatment for infants.

Recent data showed that a new HS-IGA tool for hidradenitis suppurativa addressed several concerns of prior tools but also maintained certain limitations.

IgE-mediated children with cow’s milk allergies switching from amino acid-based formula to a new formula showed strong tolerance and better acquisition of immune tolerance, suggesting other studies combining treatments may be useful.

New data indicates that unawareness of declines in memory was more associated with Alzheimer’s than awareness, providing physicians with a greater understanding of cognitive decline.

In this interview, Bhutani discussed a recent peer-reviewed study which highlighted concerns over skin cancer dangers for psoriasis patients treated with methotrexate.

New research found that certain systemic markers in psoriatic arthritis and psoriasis patients correlated with PASI scores, indicating the clinical relevance of platelets and neutrophils in inflammation.

Mehmi described some of the major challenges to diagnosing mucosal melanoma in patients, as well as the small amount of data around treating the rare but dangerous condition.

This interview featured Mehmi discussing a less well-known form of melanoma known as mucosal melanoma, a condition which he believes needs to be researched in greater depth.

Findings from a Canadian routine care study showed that brodalumab was found to be effective for those with plaque psoriasis, with future real-world setting studies needed to learn more.

This study evaluated tranexamic acid injection for post-acne vulgaris erythema, though its smaller sample size may require the findings to be reproduced in large-scale studies.

Research indicates greater expertise in the non-invasive technique for diagnosis of basal cell carcinoma may be useful, although remote supervision of novice assessors by an expert may also help.

Greater improvement in mild cognitive impairment for older adults with positive beliefs about age suggests a link between cognitive health and cultural or societal influences.

New research showed mixed results with perturbation-based balance training, or PBT, for older adults living in communities and their rate of falls.

New data on US Medicare beneficiaries indicates that the head and neck region of the body was most commonly affected by squamous cell carcinomas compared to other areas.